© 1998 American Heart Association, Inc.
Original Contributions |
Lysophosphatidylcholine Is Involved in the Antigenicity of Oxidized LDL
From the Department of Medicine, Unit of Rheumatology and CMM, Karolinska Hospital (R.W., Y.H.H., J.F.); and the Department of Medicine, King Gustaf V Research Institute, Karolinska Institute (L.S.E.), Stockholm, Sweden.
Correspondence to Johan Frostegard, Department of Medicine, Karolinska Hospital, 17177 Stockholm, Sweden.
Abstract—Lysophosphatidylcholine (LPC) is formed by hydrolysis of PC in low density lipoprotein (LDL) and cell membranes by phospholipase A2 or by oxidation. Oxidized (ox) LDL activates endothelial cells, an effect mimicked by LPC. oxLDL also has the capacity to activate T and B cells, and antibody titers to oxLDL are related to the degree of atherosclerosis. The antigen in oxLDL responsible for its immune-stimulatory capacity is not well characterized, and we hypothesized that LPC was involved. We demonstrate herein the presence of antibodies against LPC, both of the IgG and IgM isotype, in 210 healthy individuals. This antibody reactivity was not specifically related to oxidation of the fatty acid moiety in LPC, since LPC containing only palmitic acid showed antibody titers equivalent to those of LPC containing unsaturated fatty acids. Antibody titers to PC were low compared with LPC, and hydrolysis of PC at the sn-2 position is thus essential for immune reactivity. There was a close correlation between anti-oxLDL and anti-LPC antibodies. Furthermore, LPC competitively inhibited anti-oxLDL reactivity, which indicates that LPC may explain a significant part of the immune-stimulatory properties of oxLDL. LPC, being a lipid, is not likely to be an antigen itself. Instead, LPC could form immunogenic complexes with peptides, which may induce and potentiate immune reactions in the vessel wall. This study adds to the evidence that LPC is an important component of oxLDL and emphasizes the potential role of phospholipase A2 in atherosclerosis.
Key Words: lysophosphatidylcholine • antibodies • oxidized LDL • autoimmune diseases • atherosclerosis
This article has been cited by other articles:
 |
|
 |
|
  S. G. Tsouli, D. N. Kiortsis, V. Xydis, M. I. Argyropoulou, M. Elisaf, and A. D. Tselepis Antibodies Against Various Forms of Mildly Oxidized Low-Density Lipoprotein Are Not Associated With Carotid Intima-Media Thickness in Patients With Primary Hyperlipidemia Angiology, October 1, 2006; 57(5): 615 - 622. [Abstract] [PDF]
|
|
|
|
 |
|
 S. G. Tsouli, D. N. Kiortsis, E. S. Lourida, V. Xydis, L. D. Tsironis, M. I. Argyropoulou, M. Elisaf, and A. D. Tselepis Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia J. Lipid Res., October 1, 2006; 47(10): 2208 - 2214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Frostegard Atherosclerosis in Patients With Autoimmune Disorders Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1776 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mehta Lysophosphatidylcholine: an enigmatic lysolipid Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L174 - L175. [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Szmitko, C.-H. Wang, R. D. Weisel, G. A. Jeffries, T. J. Anderson, and S. Verma Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation: Part II Circulation, October 28, 2003; 108(17): 2041 - 2048. [Full Text] [PDF]
|
|
|
|
|
|
K. Arakawa, K. Isoda, T. Ito, K. Nakajima, T. Shibuya, and F. Ohsuzu Fluorescence Analysis of Biochemical Constituents Identifies Atherosclerotic Plaque With a Thin Fibrous Cap Arterioscler Thromb Vasc Biol, June 1, 2002; 22(6): 1002 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Wu, C. Lemne, U. de Faire, and J. Frostegard Antibodies to Lysophosphatidylcholine Are Decreased in Borderline Hypertension Hypertension, January 1, 2001; 37(1): 154 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. MANZI, M. C. M WASKO, and S. MANZI Inflammation-mediated rheumatic diseases and atherosclerosis Ann Rheum Dis, May 1, 2000; 59(5): 321 - 325. [Full Text]
|
|
|
|
 |
|
 S. Manzi Systemic lupus erythematosus: a model for atherogenesis? Rheumatology, April 1, 2000; 39(4): 353 - 359. [Full Text] [PDF]
|
|
|
|
|
|
S. Parthasarathy, N. Santanam, S. Ramachandran, and O. Meilhac Oxidants and antioxidants in atherogenesis: an appraisal J. Lipid Res., December 1, 1999; 40(12): 2143 - 2157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Wilson, J. B. Waldrip, K. H. Nielson, A. M. Judd, S. K. Han, W. Cho, P. J. Sims, and J. D. Bell Mechanisms by Which Elevated Intracellular Calcium Induces S49 Cell Membranes to Become Susceptible to the Action of Secretory Phospholipase A2 J. Biol. Chem., April 23, 1999; 274(17): 11494 - 11504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J George, D Harats, B Gilburd, Y Levy, P Langevitz, and Y Shoenfeld Atherosclerosis-related markers in systemic lupus erythematosus patients: The role of humoral immunity in enhanced atherogenesis Lupus, March 1, 1999; 8(3): 220 - 226. [Abstract] [PDF]
|
|
|
|
|
|
H. Peilot, B. Rosengren, G. Bondjers, and E. Hurt-Camejo Interferon-gamma Induces Secretory Group IIA Phospholipase A2 in Human Arterial Smooth Muscle Cells. INVOLVEMENT OF CELL DIFFERENTIATION, STAT-3 ACTIVATION, AND MODULATION BY OTHER CYTOKINES J. Biol. Chem., July 21, 2000; 275(30): 22895 - 22904. [Abstract] [Full Text] [PDF]
|
|